ClinicalTrials.gg
CompletedNCT02806505Updated Oct 31, 2016Results posted

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

A Phase 3 interventional study of Peginterferon alfa-2a in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 22 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
49th of 83
81 · median 129
Started
2004
with 7 others
Phase 3
19 of 83
none open now
Registered
80th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 49th largest by enrollment, is one of 8 that started in 2004, is one of 19 in phase 3, and was the 80th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum virus ribonucleic acid (HCV RNA) quantifiable at greater than (>) 600 IU/mL
  • Liver consistent with chronic hepatitis C infection obtained within 2 years of enrollment
  • Compensated liver disease without cirrhosis
  • Participants with end-stage renal disease undergoing hemodialysis
  • Negative serum pregnancy test (for women of ) documented within the 24-hour period prior to the first dose of study drug
  • All fertile participants must have been using effective during treatment with study drug

Exclusion criteria

Exclusion Criteria:

  • Interferon therapy at any previous time
  • Liver cirrhosis
  • Signs and symptoms of hepatocellular carcinoma
  • History or other evidence of decompensated liver disease
  • Any drug less than or equal to 6 weeks prior to the first dose of study drug
  • History or other evidence of a medical condition associated with chronic liver disease other than (e.g., hemochromatosis, hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
  • Poorly controlled diabetes
  • Thyroid dysfunction not adequately controlled
  • Evidence of severe retinopathy or ophthalmological disorder
  • Severe hyperparathyroidism defined as intact Parathyroid Hormone (PTH) > 800 picogram/milliliter (pg/mL)
  • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment ≤ 6 months prior to the first dose of study drug
  • Acute renal failure
  • Women with ongoing pregnancy or breast feeding
  • Positive test at screening for anti-HAV IgM Ab (hepatitis A virus immunoglobulin M antibody), surface antigen (HBsAg), anti-HBc (hepatitis B core) IgM Ab, anti- (human immunodeficiency virus) Ab
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Peginterferon alfa-2a 135 microgram (mcg)

    Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.

    Drug: Peginterferon alfa-2a

  • Experimental
    Peginterferon alfa-2a 90 mcg

    Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.

    Drug: Peginterferon alfa-2a

Interventions

  • Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment

    SVR was defined as the percentage of patients with undetectable HCV RNA. SVR rate was calculated as the number of participants with an undetectable HCV RNA divided by the number of participants of the respective participant population. The last single HCV RNA less than (\<) 50 international units per millilitre (IU/mL) measured \>=140 days after treatment end (i.e., \>= 20 weeks after treatment end) was used to determine SVR. Participants without measurements in this time window were considered to be nonresponders.

    Time frame: 24 weeks after end of treatment (Week 72)

Secondary outcomes

  1. Percentage of Participants With Virological Response (Non-detectable Hepatitis C Virus-ribonucleic Acid [HCV RNA]) at End of Treatment (EOT)

    Virological response at the end of study treatment was defined as the percentage of participants with undetectable HCV RNA. This response rate at end of treatment was calculated as the number of participants with undetectable HCV RNA divided by the number of participants of the respective participant population.

    Time frame: EOT (Week 48)

  2. Percentage of Participants With Virological Response (at Least a 2-log 10 Decrease in HCV RNA as Compared With Baseline or Unquantifiable [Less Than {<} 600 International Unit/Milliliter {IU/mL}] or Undetectable HCV RNA [< 50 IU/mL]) at Week 12 and 24

    Virological response at Weeks 12 and 24 was computed as the percentage of participants with at least a 2-log 10 decrease in HCV RNA at Weeks 12 and 24 as compared with baseline or with an unquantifiable (\< 600 IU/mL) or an undetectable HCV RNA test result (\< 50 IU/mL) at Week 12 and at Week 24, calculated as the number of participants meeting this criterion divided by the number of participants of the respective participant population.

    Time frame: Weeks 12 and 24

07

Results

Posted Oct 31, 2016

Participant flow

Participant flow — Overall Study
MilestonePeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
Started3843
Completed2832
Not completed1011
Withdrew: Adverse event/intercurrent illness13
Withdrew: Death40
Withdrew: Did not cooperate/refused treatment33
Withdrew: Failure to return01
Withdrew: Insufficient therapeutic response24

Outcome measures

PrimaryPercentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment

SVR was defined as the percentage of patients with undetectable HCV RNA. SVR rate was calculated as the number of participants with an undetectable HCV RNA divided by the number of participants of the respective participant population. The last single HCV RNA less than (\<) 50 international units per millilitre (IU/mL) measured \>=140 days after treatment end (i.e., \>= 20 weeks after treatment end) was used to determine SVR. Participants without measurements in this time window were considered to be nonresponders.

Time frame:
24 weeks after end of treatment (Week 72)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment
percentage of participantsPeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment39.5 (24.0 to 56.6)34.9 (21.0 to 50.9)
Statistical analysis
  • Peginterferon Alfa-2a 135 Microgram (mcg) vs Peginterferon Alfa-2a 90 mcg · Cochran-Mantel-Haenszel · p = 0.6746 (Assessed by Cochran-Mantel-Haenszel test stratified by country (Brazil, France, Other) and HCV genotype (1 vs. non-1).) · Odds ratio (or): 1.22 · 95% CI 0.49 to 3.06
SecondaryPercentage of Participants With Virological Response (Non-detectable Hepatitis C Virus-ribonucleic Acid [HCV RNA]) at End of Treatment (EOT)

Virological response at the end of study treatment was defined as the percentage of participants with undetectable HCV RNA. This response rate at end of treatment was calculated as the number of participants with undetectable HCV RNA divided by the number of participants of the respective participant population.

Time frame:
EOT (Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response (Non-detectable Hepatitis C Virus-ribonucleic Acid [HCV RNA]) at End of Treatment (EOT)
percentage of participantsPeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
Percentage of Participants With Virological Response (Non-detectable Hepatitis C Virus-ribonucleic Acid [HCV RNA]) at End of Treatment (EOT)57.9 (40.8 to 73.7)48.8 (33.3 to 64.5)
Statistical analysis
  • Peginterferon Alfa-2a 135 Microgram (mcg) vs Peginterferon Alfa-2a 90 mcg · Cochran-Mantel-Haenszel · p = 0.3923 (Assessed by Cochran-Mantel-Haenszel test stratified by country (Brazil, France, Other) and HCV genotype (1 vs. non-1).) · Odds ratio (or): 1.51 · 95% CI 0.60 to 3.76
SecondaryPercentage of Participants With Virological Response (at Least a 2-log 10 Decrease in HCV RNA as Compared With Baseline or Unquantifiable [Less Than {<} 600 International Unit/Milliliter {IU/mL}] or Undetectable HCV RNA [< 50 IU/mL]) at Week 12 and 24

Virological response at Weeks 12 and 24 was computed as the percentage of participants with at least a 2-log 10 decrease in HCV RNA at Weeks 12 and 24 as compared with baseline or with an unquantifiable (\< 600 IU/mL) or an undetectable HCV RNA test result (\< 50 IU/mL) at Week 12 and at Week 24, calculated as the number of participants meeting this criterion divided by the number of participants of the respective participant population.

Time frame:
Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response (at Least a 2-log 10 Decrease in HCV RNA as Compared With Baseline or Unquantifiable [Less Than {<} 600 International Unit/Milliliter {IU/mL}] or Undetectable HCV RNA [< 50 IU/mL]) at Week 12 and 24
percentage of participantsPeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
Week 1271.1 (54.1 to 84.6)69.8 (53.9 to 82.8)
Week 2465.8 (48.6 to 80.4)72.1 (56.3 to 84.7)
Statistical analysis
  • Peginterferon Alfa-2a 135 Microgram (mcg) vs Peginterferon Alfa-2a 90 mcg · Cochran-Mantel-Haenszel · p = 0.8843 (Assessed by Cochran-Mantel-Haenszel test stratified by country (Brazil, France, Other) and HCV genotype (1 vs. non-1).) · Odds ratio (or): 1.07 · 95% CI 0.43 to 2.68
  • Peginterferon Alfa-2a 135 Microgram (mcg) vs Peginterferon Alfa-2a 90 mcg · Cochran-Mantel-Haenszel · p = 0.5866 (Assessed by Cochran-Mantel-Haenszel test stratified by country (Brazil, France, Other) and HCV genotype (1 vs. non-1).) · Odds ratio (or): 0.75 · 95% CI 0.28 to 2.04

Adverse events

Collected over Baseline up to follow up period (Week 72). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2a 135 Microgram (mcg)—14/38 (36.8%)30/38 (78.9%)
Peginterferon Alfa-2a 90 mcg—14/43 (32.6%)38/43 (88.4%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
SepsisInfections and infestations2/381/43
PneumoniaInfections and infestations1/382/43
Hyperparathyroidism secondaryEndocrine disorders0/382/43
Arthritis bacterialInfections and infestations1/380/43
Bacterial infectionInfections and infestations1/380/43
EndocarditisInfections and infestations1/380/43
Viral infectionInfections and infestations1/380/43
Coronary artery diseaseCardiac disorders1/381/43
Acute coronary syndromeCardiac disorders1/380/43
Cardiac failureCardiac disorders1/380/43
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPeginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcg
AnaemiaBlood and lymphatic system disorders14/3814/43
HypertensionVascular disorders5/3814/43
HeadacheNervous system disorders9/3813/43
MyalgiaMusculoskeletal and connective tissue disorders7/388/43
AstheniaGeneral disorders7/387/43
FatigueGeneral disorders6/387/43
PyrexiaGeneral disorders5/387/43
Influenza like illnessGeneral disorders6/386/43
Hyperparathyroidism secondaryEndocrine disorders4/386/43
ArthralgiaMusculoskeletal and connective tissue disorders5/381/43

Baseline characteristics

The intent-to-treat (ITT) analysis population included all the randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Peginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcgTotal
Mean44.2 ± 11.2642.9 ± 11.2643.5 ± 11.21
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2a 135 Microgram (mcg)Peginterferon Alfa-2a 90 mcgTotal
Female15924
Male233457
08

Study locations

22 sites
  • Graz, 8036, Austria
  • Wien, 1090, Austria
  • Brasilia, 70335-000, Brazil
  • Porto Alegre, 90035-003, Brazil
  • Sao Jose Rio Preto, 15090-003, Brazil
  • Sao Luis, 78048-790, Brazil
  • Sao Paulo, 04023-900, Brazil
  • Creteil, 94010, France
  • Le Kremlin-bicetre, 94275, France
  • Marseille, 13385, France
  • Paris, 75747, France
  • Strasbourg, 67091, France
  • Toulouse, 31059, France
  • Athens, 11527, Greece
  • Nikea, 18354, Greece
  • Medan, 20119, Indonesia
  • Cagliari, 09134, Italy
  • Istanbul, 34303, Turkey
  • Istanbul, 34390, Turkey
  • Istanbul, 34662, Turkey
  • Izmir, 35040, Turkey
  • Abu Dhabi, United Arab Emirates
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2016
First posted
Jun 20, 2016
Start
Jun 2004
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Results first posted
Oct 31, 2016
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02806505
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 20, 2016
Start date
Jun 2004
Primary completion
Aug 2007
Completion
Aug 2007
Results posted
Oct 31, 2016
Last update
Oct 31, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion